Compare Stocks: QNCX, ENGN, GNLX, and AADI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$4.46 -4.7%	$4.13	$1.21 ▼ $3.81	$110.15M	0.68	261,100 shs	274,478 shs
ENGN enGene	$1.70	$1.78	$1.40 ▼ $12.25	$113.88M	-0.28	1.04 million shs	623,305 shs
GNLX Genelux	$2.70 -1.5%	$2.89	$2.29 ▼ $8.53	$121.07M	0.6	225,909 shs	265,100 shs
QNCX Quince Therapeutics	$34.12 +0.2%	$21.01	$15.10 ▼ $909.98	$34.80M	1.36	235,769 shs	38,987 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	0.00%	-6.30%	+14.65%	-5.11%	+178.75%
ENGN enGene	0.00%	-5.56%	-6.59%	+8.28%	-53.80%
GNLX Genelux	0.00%	+3.01%	-4.53%	-3.86%	-23.03%
QNCX Quince Therapeutics	0.00%	+12.72%	+80.30%	+71.09%	-89.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$4.46 -4.7%	$4.13	$1.21 ▼ $3.81	$110.15M	0.68	261,100 shs	274,478 shs
ENGN enGene	$1.70	$1.78	$1.40 ▼ $12.25	$113.88M	-0.28	1.04 million shs	623,305 shs
GNLX Genelux	$2.70 -1.5%	$2.89	$2.29 ▼ $8.53	$121.07M	0.6	225,909 shs	265,100 shs
QNCX Quince Therapeutics	$34.12 +0.2%	$21.01	$15.10 ▼ $909.98	$34.80M	1.36	235,769 shs	38,987 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	0.00%	-6.30%	+14.65%	-5.11%	+178.75%
ENGN enGene	0.00%	-5.56%	-6.59%	+8.28%	-53.80%
GNLX Genelux	0.00%	+3.01%	-4.53%	-3.86%	-23.03%
QNCX Quince Therapeutics	0.00%	+12.72%	+80.30%	+71.09%	-89.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AADI Aadi Bioscience	0.00	N/A	N/A	N/A
ENGN enGene	2.14	Hold	$11.05	551.65% Upside
GNLX Genelux	2.50	Moderate Buy	$18.00	581.82% Upside
QNCX Quince Therapeutics	2.27	Hold	$310.50	806.04% Upside

Current Analyst Ratings Breakdown

Latest QNCX, ENGN, GNLX, and AADI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	ENGN enGene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/12/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/29/2026	QNCX Quince Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$82.00
7/17/2026	GNLX Genelux	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/29/2026	QNCX Quince Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2026	QNCX Quince Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/24/2026	QNCX Quince Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$80.00
6/23/2026	QNCX Quince Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$80.00
6/23/2026	QNCX Quince Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$80.00
6/18/2026	ENGN enGene	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Equal Weight ➝ Underweight	$3.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AADI Aadi Bioscience	$25.07M	4.39	N/A	N/A	$4.29 per share	1.04
ENGN enGene	N/A	N/A	N/A	N/A	$2.60 per share	N/A
GNLX Genelux	$10K	11,837.76	N/A	N/A	$0.30 per share	8.80
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	($128.18) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AADI Aadi Bioscience	-$65.76M	-$2.35	N/A	N/A	N/A	-246.06%	-71.87%	-57.28%	N/A
ENGN enGene	-$117.30M	-$2.17	N/A	N/A	N/A	N/A	-56.06%	-45.64%	9/14/2026 (Estimated)
GNLX Genelux	-$32.15M	-$0.86	N/A	N/A	N/A	N/A	-205.85%	-138.79%	11/4/2026 (Estimated)
QNCX Quince Therapeutics	-$83.98M	-$156.71	N/A	N/A	N/A	N/A	N/A	-154.49%	N/A

Latest QNCX, ENGN, GNLX, and AADI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/14/2026	Q3 2026	ENGN enGene	-$0.47	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	QNCX Quince Therapeutics	-$28.02	-$12.31	+$15.71	-$12.31	N/A	N/A
8/13/2026	Q2 2026	GNLX Genelux	-$0.1967	-$0.21	-$0.0133	-$0.21	N/A	N/A
6/15/2026	Q2 2026	ENGN enGene	-$0.48	-$0.43	+$0.05	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A
ENGN enGene	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AADI Aadi Bioscience	N/A	4.89	4.54
ENGN enGene	0.10	12.57	12.57
GNLX Genelux	N/A	2.39	2.39
QNCX Quince Therapeutics	N/A	2.92	2.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AADI Aadi Bioscience	52.08%
ENGN enGene	64.16%
GNLX Genelux	37.33%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
AADI Aadi Bioscience	37.30%
ENGN enGene	10.50%
GNLX Genelux	7.50%
QNCX Quince Therapeutics	7.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AADI Aadi Bioscience	40	24.70 million	15.49 million	No Data
ENGN enGene	31	66.99 million	59.95 million	N/A
GNLX Genelux	10	44.84 million	41.48 million	Not Optionable
QNCX Quince Therapeutics	60	1.02 million	945,000	Optionable

QNCX, ENGN, GNLX, and AADI Headlines

Recent News About These Companies

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

August 14 at 8:00 AM | globenewswire.com

Quince Therapeutics (QNCX) Projected to Announce Earnings on Tuesday

August 9, 2026 | americanbankingnews.com

Quince Therapeutics

July 6, 2026 | fool.com

Quince Therapeutics Stock Short Interest Report | NASDAQ:QNCX | Benzinga

July 2, 2026 | benzinga.com

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

June 30, 2026 | globenewswire.com

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

June 11, 2026 | seekingalpha.com

Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy

June 2, 2026 | insidermonkey.com

Quince Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk

May 24, 2026 | theglobeandmail.com

Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript

May 18, 2026 | seekingalpha.com

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026 | globenewswire.com

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026 | globenewswire.com

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

May 18, 2026 | globenewswire.com

Quince Therapeutics (QNCX) price target increased by 100.00% to 81.60

May 15, 2026 | msn.com

Quince Therapeutics (QNCX) price target increased by 900.00% to 40.80

April 28, 2026 | msn.com

Quince Therapeutics Delays Annual 10-K Filing

April 27, 2026 | theglobeandmail.com

Quince Therapeutics settles $16.4M debt with $5.5M payment

March 30, 2026 | msn.com

Why did QNCX stock surge 40% in pre-market today?

March 30, 2026 | msn.com

Quince Therapeutics Settles Approximately $16.4 Million of Debt

March 30, 2026 | businesswire.com

Bankruptcy threat looms as Quince runs out of options

February 13, 2026 | pharmaphorum.comP

Quince Therapeutics stock plummets after revealing strategic alternatives

February 13, 2026 | au.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

QNCX, ENGN, GNLX, and AADI Company Descriptions

Aadi Bioscience NASDAQ:AADI

$4.46 -0.22 (-4.70%)

As of 08/14/2026

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

enGene NASDAQ:ENGN

$1.70 0.00 (0.00%)

As of 04:00 PM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Genelux NASDAQ:GNLX

$2.70 -0.04 (-1.46%)

As of 04:00 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Quince Therapeutics NASDAQ:QNCX

$34.12 +0.08 (+0.24%)

As of 04:00 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNCX, ENGN, GNLX, and AADI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNCX, ENGN, GNLX, and AADI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNCX, ENGN, GNLX, and AADI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

QNCX, ENGN, GNLX, and AADI Company Descriptions

Aadi Bioscience NASDAQ:AADI

enGene NASDAQ:ENGN

Genelux NASDAQ:GNLX

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNCX, ENGN, GNLX, and AADI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNCX, ENGN, GNLX, and AADI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNCX, ENGN, GNLX, and AADI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

QNCX, ENGN, GNLX, and AADI Company Descriptions

Aadi Bioscience NASDAQ:AADI

enGene NASDAQ:ENGN

Genelux NASDAQ:GNLX

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools